Quality of life and treatment satisfaction in Spanish epilepsy patients on monotherapy with lamotrigine or valproic acid

Seizure

Volumn 19, Issue 7, 2010, Pages 432-438

  Viteri, C ^a   Codina, M ^b   Cobaleda, S ^e   Lahuerta, J ^e   Barriga, J ^c   Morales, M D ^d  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^e GLAXOSMITHKLINE   (Spain)

Author keywords

Epilepsy; Health related quality of life (HRQoL); Lamotrigine; QOLIE 10; Valproic acid

Indexed keywords

LAMOTRIGINE; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIZZINESS; DRUG INDUCED HEADACHE; EPILEPSY; FATIGUE; FEMALE; FOCAL EPILEPSY; FOLLOW UP; GENERALIZED EPILEPSY; HAIR LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUALITY OF LIFE IN EPILEPSY INVENTORY; RATING SCALE; SELF CONCEPT; SIDE EFFECT; SOMNOLENCE; TREMOR; WEIGHT GAIN;

EID: 77955984518     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2010.06.014     Document Type: Article

References (28)

1. World Health Organization. Epilepsy. Fact sheets no. 1999. WHO; 2009. Available from: http://www.who.int/mediacentre/factsheets/fs999/en/index.html [accessed 18.03.09].
2. Sridharan R. Epidemiology of epilepsy. Curr Sci 2002;82:664-70.
3. Kaminow L, Schimschock JR, Hammer AE, Vuong A. Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. Epilepsy Behav 2003;4:659-66.
4. Christensen J, Kjeldsen MJ, Andersen H, Friis ML, Sidenius P. Gender differences in epilepsy. Epilepsia 2005;46:956-60.
5. Frye CA. Hormonal influences on seizures: basic neurobiology. Int Rev Neurobiol 2008;83:27-77.
6. Crawford P, Appleton R, Betts T, Duncan J, Guthrie E, Morrow J. Best practice guidelines for the management of women with epilepsy. The Women with Epilepsy Guidelines Development Group. Seizure 1999;8:201-17.
7. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002;16:695-714.
8. Feely M. Fortnightly review: drug treatmentofepilepsy. BMJ 1999;318:106-9.
9. Allain H, Schück S, Nachit-Ouineckh F, Plouin P, Brunon AM, Boulliat J. Improvement in quality of life after initiation of lamotrigine therapy in patients with epilepsy in a naturalistic treatment setting. Seizure 2007;16:173-84.
10. Aldenkamp AP, Baker G. A systematic review of the effects of lamotrigine on cognitive function and quality of life. Epilepsy Behav 2001;2:85-91.
11. Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD. Safetyoflong-term lamotrigine in epilepsy. Epilepsia 1997;38:881-6.
12. Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998;39(Suppl. 7):S22-6.
13. Stavem K, Loge JH, Kaasa S. Health status of people with epilepsy compared with a general reference population. Epilepsia 2000;41:85-90.
14. Guekht AB, Mitrokhina TV, Lebedeva AV, Dzugaeva FK, Milchakova LE, Lokshina OB, et al. Factors influencing on quality of life in people with epilepsy. Seizure 2007;16:128-33.
15. Wagner AK, Bungay KM, Kosinski M, Bromfield EB, Ehrrenberg BL. The health status of adults with epilepsy compared with that of people without chronic conditions. Pharmacotherapy 1996;16:1-9.
16. Ware JE, Sherbourne CD. The MOS 36-item short form health survey (SF-36). Med Care 1992;30:473-83.
17. Torres X, Arroyo S, Araya S, de Pablo J. The Spanish version of the Quality of Life in Epilepsy Inventory (QOLIE-31): translation, validity, and reliability. Epilepsia 1999;40:1299-304.
18. Viteri C, Codina M, Cobaleda S, Lahuerta J, Barriga J, Barrera S, et al. Validació n de la versión española del cuestionario de calidad de vida en epilepsia QOLIE-10. Neurología 2008;23:157-67.
19. Cramer JA, Van Hammée G, N132 Study Group. Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam. Epilepsy Behav 2003;4:118-23.
20. Loiseau PJ. Clinical experience with new antiepileptic drugs: antiepileptic drugs in Europe. Epilepsia 1999;40(Suppl. 6):S3-8.
21. Steinhoff BJ, Ueberall MA, Siemes H, Kurlemann G, Schmitz B, Bergmann L, et al. The LAM-SAFE Study: lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure 2005;14:597-605.
22. Sackellares JC, Kwong WJ, Vuong A, Hammer AE, Barrett PS. Lamotrigine monotherapy improves health-related quality of life in epilepsy: a doubleblind comparison with valproate. Epilepsy Behav 2002;3:376-82.
23. Balabanov PP, Zahariev ZI, Mateva NG. Evaluation of the factors affecting the quality of life and total costs in epilepsy patients on monotherapy with carbamazepine and valproate. Folia Med (Plovdiv) 2008;50:18-23.
24. Marson AG, Appleton R, Baker GA, Chadwick DW, Doughty J, Eaton B, et al. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Health Technol Assess 2007; 11. iii-iv, ix-x, 1-134.
25. Aldenkamp AP, Van Donselaar CA, Flamman H, Lafarre DLW. Psychosocial reactions to the epilepsy in an unselected group of patients with epilepsy under treatment in general hospitals. Seizure 2003;12:101-6.
26. Piazzini A, Beghi E, Turner K, Ferraroni M, LICE Quality of Life Group. Healthrelated quality of life in epilepsy: findings obtained with a new Italian instrument. Epilepsy Behav 2008;13:119-26.
27. Vazquez B, Gibson P, Kustra R. Epilepsy and women's health issues: unmet needs-survey results from women with epilepsy. Epilepsy Behav 2007;10:163-9.
28. Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-7.